Study of targeted drug delivery into the abdomen using PIPAC
Treatments studied
Part of Cancer, Digestive system, Hormones & metabolism, Women’s health & pregnancy clinical trials.
This Phase 1 trial tests PIPAC, a way to deliver anti-cancer medicine directly into the abdomen using a minimally invasive procedure. It is for people with peritoneal spread from certain cancers to see whether this approach is safe and potentially helpful.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have confirmed ovarian, uterine, stomach, appendix, or colorectal cancer that has spread to the lining of the abdomen (peritoneal carcinomatosis).
- You must be able to sign consent (or have a legally authorized representative), and be well enough for treatment (ECOG 0–2).
- Your blood counts and organ tests must be within required ranges (white blood cells/neutrophils, platelets, hemoglobin, bilirubin, liver enzymes, and kidney function).
- Your cancer must have progressed after prior cancer treatment (or, for one group, been stable or responsive during first-line treatment for several months).
- A doctor must be able to do the planned laparoscopy: medicine access is feasible, there’s limited fluid buildup, no signs of an impending bowel blockage, and you are not a candidate for cytoreduction/HIPEC.
- You must not have certain major complications (like uncontrolled infection, significant heart problems, pregnancy, or certain prior reactions or dose limits to specific drugs).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new way to deliver chemotherapy directly into the belly for stomach cancer that has spread to the lining of the abdomen (peritoneal metastases). It also combines two standard chemotherapy drugs. The goal is to see if this approach can help people whose cancer progressed after first treatment.
This trial tests a new way to deliver chemotherapy directly into the abdomen (called PIPAC) for people with cancer spread to the lining of the belly. It uses the drug mitomycin and is for patients who cannot have standard surgery or heated chemotherapy.
This trial tests a special chemotherapy delivery method called PIPAC (pressurized intraperitoneal aerosol chemotherapy) for ovarian cancer that has spread within the abdomen. The goal is to deliver cancer-fighting drugs more effectively directly to where the cancer is.
This Phase 2 study tests whether spraying chemotherapy into the abdomen (through a small procedure) after colon cancer surgery can lower the chance the cancer comes back. It is meant for people with high-risk tumor features but who have had surgery and have no proven relapse yet.
This Phase 1 study tests a new way to deliver chemotherapy inside the abdomen (belly) using a pressurized aerosol during a procedure, along with standard blood (IV) chemotherapy. It may help people with advanced ovarian cancer whose tumors have not progressed but are not removable with surgery yet.
This trial looks at a way to give chemotherapy into the abdomen (through a small tube during laparoscopy) for certain stomach cancers. It aims to see whether this approach improves cancer control and surgical outcomes for people whose tumors can potentially be removed.
Hear when a new Clinical Stage IV Gastric Cancer AJCC v8 trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.